Risk-adapted Treatment of Pediatric Acute Lymphoblastic Leukemia

Hematology/Oncology Clinics of North America

Volumn 23, Issue 5, 2009, Pages 973-990

  Jeha, Sima ^a   Pui, Ching Hon ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

ALL biology; ALL treatment; Pediatric leukemia; Risk adapted therapy

Indexed keywords

ANTHRACYCLINE; ANTILEUKEMIC AGENT; ANTIMETABOLITE; ASPARAGINASE; ASPARAGINASE MACROGOL; CD20 ANTIBODY; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; EPRATUZUMAB; GLUCOCORTICOID; HYDROCORTISONE; IMMUNOTOXIN; MERCAPTOPURINE; METHOTREXATE; MITOXANTRONE; MONOCLONAL ANTIBODY; NELARABINE; PREDNISOLONE; PREDNISONE; PROTEIN TYROSINE KINASE INHIBITOR; PURINE NUCLEOSIDE DERIVATIVE; RECOMBINANT CD22 ANTIBODY IMMUNOTOXIN; TIOGUANINE; UNCLASSIFIED DRUG; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; BEDTIME DOSAGE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BRAIN HEMORRHAGE; CANCER RADIOTHERAPY; CANCER RECURRENCE; CELL LEVEL; CENTRAL NERVOUS SYSTEM METASTASIS; CHILD; CHILDHOOD LEUKEMIA; CLINICAL TRIAL; CYTOGENETICS; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG TARGETING; DRUG WITHDRAWAL; GENOME ANALYSIS; HUMAN; IMMUNOPHENOTYPING; LEUKEMIA; LEUKEMIA CELL; LEUKEMIA REMISSION; LEUKOCYTE COUNT; LEUKOENCEPHALOPATHY; LIVER DYSFUNCTION; LIVER VENOOCCLUSIVE DISEASE; LOW DRUG DOSE; MAINTENANCE THERAPY; MENINGITIS; METASTASIS; NEUTROPENIA; NONHUMAN; ONSET AGE; OPTIMAL DRUG DOSE; PATIENT SELECTION; PHARMACOGENOMICS; POSTDURAL PUNCTURE HEADACHE; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SIDE EFFECT; SPINAL CORD DISEASE; THROMBOCYTOPENIA; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

AGE FACTORS; ANTINEOPLASTIC AGENTS; CHILD; HUMANS; LEUKOCYTE COUNT; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; REMISSION INDUCTION; RISK FACTORS; STEM CELL TRANSPLANTATION;

EID: 70349756898     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hoc.2009.07.009     Document Type: Review

References (128)

1. Burchenal J.H., Karnofsky D.A., Kingsley-Pillers E.M., et al. The effects of the folic acid antagonists and 2,6-diaminopurine on neoplastic disease, with special reference to acute leukemia. Cancer 4 3 (1951) 549-569
2. Aur R.J., Simone J.V., and Pratt C.B. Successful remission induction in children with acute lymphocytic leukemia at high risk for treatment failure. Cancer 27 6 (1971) 1332-1336
3. Smith M., Arthur D., Camitta B., et al. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol 14 1 (1996) 18-24
4. Pui C.H., and Evans W.E. Treatment of acute lymphoblastic leukemia. N Engl J Med 354 2 (2006) 166-178
5. Pui C.H., Relling M.V., and Downing J.R. Acute lymphoblastic leukemia. N Engl J Med 350 15 (2004) 1535-1548
6. Arico M., Valsecchi M.G., Camitta B., et al. Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. N Engl J Med 342 14 (2000) 998-1006
7. Mancini M., Scappaticci D., Cimino G., et al. A comprehensive genetic classification of adult acute lymphoblastic leukemia (ALL): analysis of the GIMEMA 0496 protocol. Blood 105 9 (2005) 3434-3441
8. Pui C.H., Gaynon P.S., Boyett J.M., et al. Outcome of treatment in childhood acute lymphoblastic leukaemia with rearrangements of the 11q23 chromosomal region. Lancet 359 9321 (2002) 1909-1915
9. Gleissner B., Goekbuget N., Rieder H., et al. CD 10-negative pre-B acute lymphoblastic leukemia (ALL): a distinct high-risk subgroup of adult ALL associated with a high frequency of MLL aberrations. Results of the German Multicenter Trials for Adult ALL (GMALL). Blood 106 13 (2005) 4054-4056
10. Amylon M.D., Shuster J., Pullen J., et al. Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: a Pediatric Oncology Group study. Leukemia 13 3 (1999) 335-342
11. Schrappe M., Reiter A., Ludwig W.D., et al. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. German-Austrian-Swiss ALL-BFM Study Group. Blood 95 11 (2000) 3310-3322
12. Goldberg J.M., Silverman L.B., Levy D.E., et al. Childhood T-cell acute lymphoblastic leukemia: the Dana-Farber Cancer Institute acute lymphoblastic leukemia consortium experience. J Clin Oncol 21 19 (2003) 3616-3622
13. Ravandi F., and Gandhi V. Novel purine nucleoside analogues for T-cell-lineage acute lymphoblastic leukaemia and lymphoma. Expert Opin Investig Drugs 15 12 (2006) 1601-1613
14. Coustan-Smith E., Mullighan C.G., Onciu M., et al. Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol 10 2 (2009) 147-156
15. Pui C.H., Robison L.L., and Look A.T. Acute lymphoblastic leukaemia. Lancet 371 9617 (2008) 1030-1043
16. Meijerink J.P., den Boer M.L., and Pieters R. New genetic abnormalities and treatment response in acute lymphoblastic leukemia. Semin Hematol 46 1 (2009) 16-23
17. Look A.T., Roberson P.K., Williams D.L., et al. Prognostic importance of blast cell DNA content in childhood acute lymphoblastic leukemia. Blood 65 5 (1985) 1079-1086
18. Trueworthy R., Shuster J., Look T., et al. Ploidy of lymphoblasts is the strongest predictor of treatment outcome in B-progenitor cell acute lymphoblastic leukemia of childhood: a Pediatric Oncology Group study. J Clin Oncol 10 4 (1992) 606-613
19. Synold T.W., Relling M.V., Boyett J.M., et al. Blast cell methotrexate-polyglutamate accumulation in vivo differs by lineage, ploidy, and methotrexate dose in acute lymphoblastic leukemia. J Clin Invest 94 5 (1994) 1996-2001
20. Kaspers G.J., Smets L.A., Pieters R., et al. Favorable prognosis of hyperdiploid common acute lymphoblastic leukemia may be explained by sensitivity to antimetabolites and other drugs: results of an in vitro study. Blood 85 3 (1995) 751-756
21. Ito C., Kumagai M., Manabe A., et al. Hyperdiploid acute lymphoblastic leukemia with 51 to 65 chromosomes: a distinct biological entity with a marked propensity to undergo apoptosis. Blood 93 1 (1999) 315-320
22. Nachman J.B., Heerema N.A., Sather H., et al. Outcome of treatment in children with hypodiploid acute lymphoblastic leukemia. Blood 110 4 (2007) 1112-1115
23. Harris M.B., Shuster J.J., Carroll A., et al. Trisomy of leukemic cell chromosomes 4 and 10 identifies children with B-progenitor cell acute lymphoblastic leukemia with a very low risk of treatment failure: a Pediatric Oncology Group study. Blood 79 12 (1992) 3316-3324
24. Raimondi S.C. Current status of cytogenetic research in childhood acute lymphoblastic leukemia. Blood 81 9 (1993) 2237-2251
25. Crist W., Carroll A., Shuster J., et al. Philadelphia chromosome positive childhood acute lymphoblastic leukemia: clinical and cytogenetic characteristics and treatment outcome. A Pediatric Oncology Group study. Blood 76 3 (1990) 489-494
26. Fletcher J.A., Lynch E.A., Kimball V.M., et al. Translocation (9;22) is associated with extremely poor prognosis in intensively treated children with acute lymphoblastic leukemia. Blood 77 3 (1991) 435-439
27. Pui C.H., Sandlund J.T., Pei D., et al. Results of therapy for acute lymphoblastic leukemia in black and white children. JAMA 290 15 (2003) 2001-2007
28. Raimondi S.C., Behm F.G., Roberson P.K., et al. Cytogenetics of pre-B-cell acute lymphoblastic leukemia with emphasis on prognostic implications of the t(1;19). J Clin Oncol 8 8 (1990) 1380-1388
29. Jeha S., Pei D., Raimondi S.C., et al. Increased risk for CNS relapse in pre-B cell leukemia with the t(1;19)/TCF3-PBX1. Leukemia (2009) [Epub ahead of print]
30. Garg R., Kantarjian H., Thomas D., et al. Adults with acute lymphoblastic leukemia and translocation (1;19) abnormality have a favorable outcome with hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with methotrexate and high-dose cytarabine chemotherapy. Cancer 115 10 (2009) 2147-2154
31. Moorman A.V., Richards S.M., Robinson H.M., et al. Prognosis of children with acute lymphoblastic leukemia (ALL) and intrachromosomal amplification of chromosome 21 (iAMP21). Blood 109 6 (2007) 2327-2330
32. Paulsson K., Horvat A., Strombeck B., et al. Mutations of FLT3, NRAS, KRAS, and PTPN11 are frequent and possibly mutually exclusive in high hyperdiploid childhood acute lymphoblastic leukemia. Genes Chromosomes Cancer 47 1 (2008) 26-33
33. Mullighan C.G., Su X., Zhang J., et al. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med 360 5 (2009) 470-480
34. den Boer M.L., van S.M., De Menezes R.X., et al. A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study. Lancet Oncol 10 2 (2009) 125-134
35. Mullighan C.G., Miller C.B., Radtke I., et al. BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature 453 7191 (2008) 110-114
36. Campana D. Minimal residual disease in acute lymphoblastic leukemia. Semin Hematol 46 1 (2009) 100-106
37. Pui C.H., Campana D., and Evans W.E. Childhood acute lymphoblastic leukaemia-current status and future perspectives. Lancet Oncol 2 10 (2001) 597-607
38. Pieters R., Schrappe M., De Lorenzo P., et al. A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial. Lancet 370 9583 (2007) 240-250
39. Bostrom B.C., Sensel M.R., Sather H.N., et al. Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group. Blood 101 10 (2003) 3809-3817
40. Mitchell C.D., Richards S.M., Kinsey S.E., et al. Benefit of dexamethasone compared with prednisolone for childhood acute lymphoblastic leukaemia: results of the UK Medical Research Council ALL97 randomized trial. Br J Haematol 129 6 (2005) 734-745
41. Igarashi S., Manabe A., Ohara A., et al. No advantage of dexamethasone over prednisolone for the outcome of standard- and intermediate-risk childhood acute lymphoblastic leukemia in the Tokyo Children's Cancer Study Group L95-14 protocol. J Clin Oncol 23 27 (2005) 6489-6498
42. Asselin B.L., Whitin J.C., Coppola D.J., et al. Comparative pharmacokinetic studies of three asparaginase preparations. J Clin Oncol 11 9 (1993) 1780-1786
43. Vieira Pinheiro J.P., Wenner K., Escherich G., et al. Serum asparaginase activities and asparagine concentrations in the cerebrospinal fluid after a single infusion of 2,500 IU/m(2) PEG asparaginase in children with ALL treated according to protocol COALL-06-97. Pediatr Blood Cancer 46 1 (2006) 18-25
44. Liang D.C., Hung I.J., Yang C.P., et al. Unexpected mortality from the use of E. coli L-asparaginase during remission induction therapy for childhood acute lymphoblastic leukemia: a report from the Taiwan Pediatric Oncology Group. Leukemia 13 2 (1999) 155-160
45. Ahlke E., Nowak-Gottl U., Schulze-Westhoff P., et al. Dose reduction of asparaginase under pharmacokinetic and pharmacodynamic control during induction therapy in children with acute lymphoblastic leukaemia. Br J Haematol 96 4 (1997) 675-681
46. Hak L.J., Relling M.V., Cheng C., et al. Asparaginase pharmacodynamics differ by formulation among children with newly diagnosed acute lymphoblastic leukemia. Leukemia 18 6 (2004) 1072-1077
47. Silverman L.B., Gelber R.D., Dalton V.K., et al. Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. Blood 97 5 (2001) 1211-1218
48. Douer D., Yampolsky H., Cohen L.J., et al. Pharmacodynamics and safety of intravenous pegaspargase during remission induction in adults aged 55 years or younger with newly diagnosed acute lymphoblastic leukemia. Blood 109 7 (2007) 2744-2750
49. Wetzler M., Sanford B.L., Kurtzberg J., et al. Effective asparagine depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia: Cancer and Leukemia Group B Study 9511. Blood 109 10 (2007) 4164-4167
50. Moghrabi A., Levy D.E., Asselin B., et al. Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia. Blood 109 3 (2007) 896-904
51. Duval M., Suciu S., Ferster A., et al. Comparison of Escherichia coli-asparaginase with Erwinia-asparaginase in the treatment of childhood lymphoid malignancies: results of a randomized European Organisation for Research and Treatment of Cancer-Children's Leukemia Group phase 3 trial. Blood 99 8 (2002) 2734-2739
52. Harms D.O., and Janka-Schaub G.E. Co-operative study group for childhood acute lymphoblastic leukemia (COALL): long-term follow-up of trials 82, 85, 89 and 92. Leukemia 14 12 (2000) 2234-2239
53. Hurwitz C.A., Silverman L.B., Schorin M.A., et al. Substituting dexamethasone for prednisone complicates remission induction in children with acute lymphoblastic leukemia. Cancer 88 8 (2000) 1964-1969
54. Schrappe M., Reiter A., Zimmermann M., et al. Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Berlin-Frankfurt-Munster. Leukemia 14 12 (2000) 2205-2222
55. Borowitz M.J., Devidas M., Hunger S.P., et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study. Blood 111 12 (2008) 5477-5485
56. Pui C.H., and Campana D. New definition of remission in childhood acute lymphoblastic leukemia. Leukemia 14 5 (2000) 783-785
57. Chessells J.M., Bailey C., and Richards S.M. Intensification of treatment and survival in all children with lymphoblastic leukaemia: results of UK Medical Research Council trial UKALL X. Medical Research Council Working Party on Childhood Leukaemia. Lancet 345 8943 (1995) 143-148
58. Evans W.E., Relling M.V., Rodman J.H., et al. Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. N Engl J Med 338 8 (1998) 499-505
59. Nachman J.B., Sather H.N., Sensel M.G., et al. Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy. N Engl J Med 338 23 (1998) 1663-1671
60. Gaynon P.S., Trigg M.E., Heerema N.A., et al. Children's Cancer Group trials in childhood acute lymphoblastic leukemia: 1983-1995. Leukemia 14 12 (2000) 2223-2233
61. Pui C.H., Sandlund J.T., Pei D., et al. Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research Hospital. Blood 104 9 (2004) 2690-2696
62. Loh M.L., Goldwasser M.A., Silverman L.B., et al. Prospective analysis of TEL/AML1-positive patients treated on Dana-Farber Cancer Institute Consortium Protocol 95-01. Blood 107 11 (2006) 4508-4513
63. Camitta B., Leventhal B., Lauer S., et al. Intermediate-dose intravenous methotrexate and mercaptopurine therapy for non-T, non-B acute lymphocytic leukemia of childhood: a Pediatric Oncology Group study. J Clin Oncol 7 10 (1989) 1539-1544
64. Camitta B., Mahoney D., Leventhal B., et al. Intensive intravenous methotrexate and mercaptopurine treatment of higher-risk non-T, non-B acute lymphocytic leukemia: a Pediatric Oncology Group study. J Clin Oncol 12 7 (1994) 1383-1389
65. Land V.J., Shuster J.J., Crist W.M., et al. Comparison of two schedules of intermediate-dose methotrexate and cytarabine consolidation therapy for childhood B-precursor cell acute lymphoblastic leukemia: a Pediatric Oncology Group study. J Clin Oncol 12 9 (1994) 1939-1945
66. Pui C.H., Boyett J.M., Rivera G.K., et al. Long-term results of Total Therapy studies 11, 12 and 13A for childhood acute lymphoblastic leukemia at St Jude Children's Research Hospital. Leukemia 14 12 (2000) 2286-2294
67. Pui C.H., Sallan S., Relling M.V., et al. International childhood acute lymphoblastic leukemia workshop: Sausalito, CA, 30 November-1 December 2000. Leukemia 15 5 (2001) 707-715
68. Galpin A.J., Schuetz J.D., Masson E., et al. Differences in folylpolyglutamate synthetase and dihydrofolate reductase expression in human B-lineage versus T-lineage leukemic lymphoblasts: mechanisms for lineage differences in methotrexate polyglutamylation and cytotoxicity. Mol Pharmacol 52 1 (1997) 155-163
69. Panetta J.C., Yanishevski Y., Pui C.H., et al. A mathematical model of in vivo methotrexate accumulation in acute lymphoblastic leukemia. Cancer Chemother Pharmacol 50 5 (2002) 419-428
70. Masson E., Relling M.V., Synold T.W., et al. Accumulation of methotrexate polyglutamates in lymphoblasts is a determinant of antileukemic effects in vivo. A rationale for high-dose methotrexate. J Clin Invest 97 1 (1996) 73-80
71. Kager L., Cheok M., Yang W., et al. Folate pathway gene expression differs in subtypes of acute lymphoblastic leukemia and influences methotrexate pharmacodynamics. J Clin Invest 115 1 (2005) 110-117
72. Hutchinson R.J., Gaynon P.S., Sather H., et al. Intensification of therapy for children with lower-risk acute lymphoblastic leukemia: long-term follow-up of patients treated on Children's Cancer Group Trial 1881. J Clin Oncol 21 9 (2003) 1790-1797
73. Lange B.J., Bostrom B.C., Cherlow J.M., et al. Double-delayed intensification improves event-free survival for children with intermediate-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group. Blood 99 3 (2002) 825-833
74. Cassileth P.A., Andersen J.W., Bennett J.M., et al. Adult acute lymphocytic leukemia: the Eastern Cooperative Oncology Group experience. Leukemia 6 Suppl (1992) 2178-2181
75. Riehm H., Gadner H., Henze G., et al. Results and significance of six randomized trials in four consecutive ALL-BFM studies. Haematol Blood Transfus 33 (1990) 439-450
76. Cuttner J., Mick R., Budman D.R., et al. Phase III trial of brief intensive treatment of adult acute lymphocytic leukemia comparing daunorubicin and mitoxantrone: a CALGB Study. Leukemia 5 5 (1991) 425-431
77. Toyoda Y., Manabe A., Tsuchida M., et al. Six months of maintenance chemotherapy after intensified treatment for acute lymphoblastic leukemia of childhood. J Clin Oncol 18 7 (2000) 1508-1516
78. Duration and intensity of maintenance chemotherapy in acute lymphoblastic leukaemia: overview of 42 trials involving 12 000 randomised children. Childhood ALL Collaborative Group. Lancet 347 9018 (1996) 1783-1788
79. Sather H., Miller D., Nesbit M., et al. Differences in prognosis for boys and girls with acute lymphoblastic leukaemia. Lancet 1 8223 (1981) 739-743
80. Duration of chemotherapy in childhood acute lymphoblastic leukaemia. The medical research council's working party on leukaemia in childhood. Med Pediatr Oncol 10 5 (1982) 511-520
81. Lennard L., Lilleyman J.S., Van L.J., et al. Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia. Lancet 336 8709 (1990) 225-229
82. Whitehead V.M., Vuchich M.J., Lauer S.J., et al. Accumulation of high levels of methotrexate polyglutamates in lymphoblasts from children with hyperdiploid (greater than 50 chromosomes) B-lineage acute lymphoblastic leukemia: a Pediatric Oncology Group study. Blood 80 5 (1992) 1316-1323
83. Schmiegelow K., Schroder H., Gustafsson G., et al. Risk of relapse in childhood acute lymphoblastic leukemia is related to RBC methotrexate and mercaptopurine metabolites during maintenance chemotherapy. Nordic Society for Pediatric Hematology and Oncology. J Clin Oncol 13 2 (1995) 345-351
84. Chessells J.M., Harrison G., Lilleyman J.S., et al. Continuing (maintenance) therapy in lymphoblastic leukaemia: lessons from MRC UKALL X. Medical Research Council Working Party in Childhood Leukaemia. Br J Haematol 98 4 (1997) 945-951
85. Relling M.V., Hancock M.L., Boyett J.M., et al. Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukemia. Blood 93 9 (1999) 2817-2823
86. Schmiegelow K., Glomstein A., Kristinsson J., et al. Impact of morning versus evening schedule for oral methotrexate and 6-mercaptopurine on relapse risk for children with acute lymphoblastic leukemia. Nordic Society for Pediatric Hematology and Oncology (NOPHO). J Pediatr Hematol Oncol 19 2 (1997) 102-109
87. Rivard G.E., Lin K.T., Leclerc J.M., et al. Milk could decrease the bioavailability of 6-mercaptopurine. Am J Pediatr Hematol Oncol 11 4 (1989) 402-406
88. Farrow A.C., Buchanan G.R., Zwiener R.J., et al. Serum aminotransferase elevation during and following treatment of childhood acute lymphoblastic leukemia. J Clin Oncol 15 4 (1997) 1560-1566
89. Evans W.E., Horner M., Chu Y.Q., et al. Altered mercaptopurine metabolism, toxic effects, and dosage requirement in a thiopurine methyltransferase-deficient child with acute lymphocytic leukemia. J Pediatr 119 6 (1991) 985-989
90. Relling M.V., Hancock M.L., Rivera G.K., et al. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J Natl Cancer Inst 91 23 (1999) 2001-2008
91. Pui C.H., and Relling M.V. Topoisomerase II inhibitor-related acute myeloid leukaemia. Br J Haematol 109 (2000) 13-23
92. Relling M.V., Rubnitz J.E., Rivera G.K., et al. High incidence of secondary brain tumours after radiotherapy and antimetabolites. Lancet 354 9172 (1999) 34-39
93. Evans W.E., and Relling M.V. Moving towards individualized medicine with pharmacogenomics. Nature 429 6990 (2004) 464-468
94. Relling M.V., and Dervieux T. Pharmacogenetics and cancer therapy. Nat Rev Cancer 1 2 (2001) 99-108
95. Jacobs S.S., Stork L.C., Bostrom B.C., et al. Substitution of oral and intravenous thioguanine for mercaptopurine in a treatment regimen for children with standard risk acute lymphoblastic leukemia: a collaborative Children's Oncology Group/National Cancer Institute pilot trial (CCG-1942). Pediatr Blood Cancer 49 3 (2007) 250-255
96. Harms D.O., Gobel U., Spaar H.J., et al. Thioguanine offers no advantage over mercaptopurine in maintenance treatment of childhood ALL: results of the randomized trial COALL-92. Blood 102 8 (2003) 2736-2740
97. Vora A., Mitchell C.D., Lennard L., et al. Toxicity and efficacy of 6-thioguanine versus 6-mercaptopurine in childhood lymphoblastic leukaemia: a randomised trial. Lancet 368 9544 (2006) 1339-1348
98. Lennard L., Richards S., Cartwright C.S., et al. The thiopurine methyltransferase genetic polymorphism is associated with thioguanine-related veno-occlusive disease of the liver in children with acute lymphoblastic leukemia. Clin Pharmacol Ther 80 4 (2006) 375-383
99. Conter V., Valsecchi M.G., Silvestri D., et al. Pulses of vincristine and dexamethasone in addition to intensive chemotherapy for children with intermediate-risk acute lymphoblastic leukaemia: a multicentre randomised trial. Lancet 369 9556 (2007) 123-131
100. Pui C.H., and Howard S.C. Current management and challenges of malignant disease in the CNS in paediatric leukaemia. Lancet Oncol 9 3 (2008) 257-268
101. Conter V., Schrappe M., Arico M., et al. Role of cranial radiotherapy for childhood T-cell acute lymphoblastic leukemia with high WBC count and good response to prednisone. Associazione Italiana Ematologia Oncologia Pediatrica and the Berlin-Frankfurt-Munster groups. J Clin Oncol 15 8 (1997) 2786-2791
102. Mahmoud H.H., Rivera G.K., Hancock M.L., et al. Low leukocyte counts with blast cells in cerebrospinal fluid of children with newly diagnosed acute lymphoblastic leukemia. N Engl J Med 329 5 (1993) 314-319
103. Gajjar A., Harrison P.L., Sandlund J.T., et al. Traumatic lumbar puncture at diagnosis adversely affects outcome in childhood acute lymphoblastic leukemia. Blood 96 10 (2000) 3381-3384
104. Burger B., Zimmermann M., Mann G., et al. Diagnostic cerebrospinal fluid examination in children with acute lymphoblastic leukemia: significance of low leukocyte counts with blasts or traumatic lumbar puncture. J Clin Oncol 21 2 (2003) 184-188
105. te Loo D.M., Kamps W.A., van der Does-van den Berg A., et al. Prognostic significance of blasts in the cerebrospinal fluid without pleiocytosis or a traumatic lumbar puncture in children with acute lymphoblastic leukemia: experience of the Dutch Childhood Oncology Group. J Clin Oncol 24 15 (2006) 2332-2336
106. Howard S.C., Gajjar A., Ribeiro R.C., et al. Safety of lumbar puncture for children with acute lymphoblastic leukemia and thrombocytopenia. JAMA 284 17 (2000) 2222-2224
107. Blaney S.M., Poplack D.G., Godwin K., et al. Effect of body position on ventricular CSF methotrexate concentration following intralumbar administration. J Clin Oncol 13 1 (1995) 177-179
108. Matloub Y., Lindemulder S., Gaynon P.S., et al. Intrathecal triple therapy decreases central nervous system relapse but fails to improve event-free survival when compared with intrathecal methotrexate: results of the Children's Cancer Group (CCG) 1952 study for standard-risk acute lymphoblastic leukemia, reported by the Children's Oncology Group. Blood 108 4 (2006) 1165-1173
109. Pui C.H., Cheng C., Leung W., et al. Extended follow-up of long-term survivors of childhood acute lymphoblastic leukemia. N Engl J Med 349 7 (2003) 640-649
110. Hijiya N., Hudson M.M., Lensing S., et al. Cumulative incidence of secondary neoplasms as a first event after childhood acute lymphoblastic leukemia. JAMA 297 11 (2007) 1207-1215
111. Waber D.P., Turek J., Catania L., et al. Neuropsychological outcomes from a randomized trial of triple intrathecal chemotherapy compared with 18 Gy cranial radiation as CNS treatment in acute lymphoblastic leukemia: findings from Dana-Farber Cancer Institute ALL Consortium Protocol 95-01. J Clin Oncol 25 31 (2007) 4914-4921
112. Hilden J.M., Dinndorf P.A., Meerbaum S.O., et al. Analysis of prognostic factors of acute lymphoblastic leukemia in infants: report on CCG 1953 from the Children's Oncology Group. Blood 108 2 (2006) 441-451
113. Pui C., Campana D., Pei D., Bowman W., Sandlund J., Kaste S., et al. Treatment of childhood acute lymphoblastic leukemia without prophylactic cranial irradiation. N Engl J Med 360 26 (2009) 2730-2741
114. Stam J. Thrombosis of the cerebral veins and sinuses. N Engl J Med 352 17 (2005) 1791-1798
115. Laningham F.H., Kun L.E., Reddick W.E., et al. Childhood central nervous system leukemia: historical perspectives, current therapy, and acute neurological sequelae. Neuroradiology 49 11 (2007) 873-888
116. Schultz K, Bowman W, Aledo A, Slayton W, Sather H, Devidas M, et al. Improved early event free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a Children's Oncology Study. J Clin Oncol, in press.
117. Schrauder A., Reiter A., Gadner H., et al. Superiority of allogeneic hematopoietic stem-cell transplantation compared with chemotherapy alone in high-risk childhood T-cell acute lymphoblastic leukemia: results from ALL-BFM 90 and 95. J Clin Oncol 24 36 (2006) 5742-5749
118. Moricke A., Reiter A., Zimmermann M., et al. Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. Blood 111 9 (2008) 4477-4489
119. Gruber F., Mustjoki S., and Porkka K. Impact of tyrosine kinase inhibitors on patient outcomes in Philadelphia chromosome-positive acute lymphoblastic leukaemia. Br J Haematol 145 5 (2009) 581-597
120. Gandemer V., Auclerc M.F., Perel Y., et al. Impact of age, leukocyte count and day 21-bone marrow response to chemotherapy on the long-term outcome of children with philadelphia chromosome-positive acute lymphoblastic leukemia in the pre-imatinib era: results of the FRALLE 93 study. BMC Cancer 9 (2009) 14
121. Thomas D.A., Faderl S., Cortes J., et al. Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood 103 12 (2004) 4396-4407
122. Yanada M., Takeuchi J., Sugiura I., et al. High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group. J Clin Oncol 24 3 (2006) 460-466
123. Pui C.H., and Jeha S. New therapeutic strategies for the treatment of acute lymphoblastic leukaemia. Nat Rev Drug Discov 6 2 (2007) 149-165
124. Thomas D.A., O'Brien S., Jorgensen J.L., et al. Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia. Blood 113 25 (2009) 6330-6337
125. Jeha S., Behm F., Pei D., et al. Prognostic significance of CD20 expression in childhood B-cell precursor acute lymphoblastic leukemia. Blood 108 10 (2006) 3302-3304
126. Gokbuget N., and Hoelzer D. Novel antibody-based therapy for acute lymphoblastic leukaemia. Best Pract Res Clin Haematol 19 4 (2006) 701-713
127. Raetz E.A., Cairo M.S., Borowitz M.J., et al. Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children's Oncology Group Pilot Study. J Clin Oncol 26 22 (2008) 3756-3762
128. Pastan I., Hassan R., FitzGerald D.J., et al. Immunotoxin therapy of cancer. Nat Rev Cancer 6 7 (2006) 559-565